Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Atrial Fibrillation
Interventions
DRUG

Non-coumadin Oral Anticoagulant

Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.

Trial Locations (3)

60611

Northwestern University, Chicago

02215

Beth Israel Deaconess Medical Center, Boston

N6A 5A5

University of Western Ontario, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Medtronic

INDUSTRY

lead

Northwestern University

OTHER